Search

Background The advantages of mobile smart healthcare in screening, intervention, treatment, and management of cardiovascular diseases have become increasingly prominent in recent years. The application value of wearable single lead electrocardiogram equipment in the early screening and diagnosis of arrhythmia patients out of the hospital has been recognized by scholars and clinical workers. However, its application in risk screening and long-term follow-up management of chronic disease patients in primary care is limited by the single function of the cloud platform led and matched by it. Objective To explore the application value of mobile smart healthcare in the prevention and control of cardiovascular disease risk in elderly patients with chronic disease in primary care from the perspective of chronic disease prevention and control and using wearable single lead electrocardiogram equipment as carriers, based on hierarchical medical system. Methods A total of 3 000 patients with chronic disease aged above 65 years admitted to primary care institutions in Ningxia from January 2022 to August 2022 were selected as research subjects, including 1 202 males and 1 798 females with an average age of (71.3±5.0) years. The baseline data were recorded by primary care physicians through mobile phone APP and cloud platform of patient management, 72-hour ECG data collected by wearable single lead electrocardiogram equipment were also uploaded to cloud platform of patient management. Analysis of data and risk stratification for arrhythmia, heart rate variability (HRV) and obstructive sleep apnea hypopnea syndrome (OSAHS) were performed by professional electrocardiographers, and the corresponding marks on the cloud platform for the data with low, medium and high risk of cardiovascular disease were ticked according to the stratification results of the three analysis methods. The cloud platform notifies primary care physicians of high and medium risk data in the form of SMS for the management of different processes of patients. The number of detected cases with different risk stratification, the number of detected cases and rates of management according to the process among patients with low, medium and high risk of cardiovascular disease were counted. Results Arrhythmias were detected in 1 526 (50.87%), 1 349 (44.97%), and 125 (4.17%) cases consistent with negativity, positivity, and significant positivity, respectively; HRV was mildly, moderately, and severely reduced in 2 330 (78.50%), 630 (21.23%), and 8 (0.27%) cases, respectively; OSAHS was consistent with mild, moderate, and severe abnormalities in 1 769 (59.60%), 573 (19.31%), and 626 (21.09%) cases, respectively. The comprehensive risk of cardiovascular disease was low, moderate, and high in 744 (24.80%), 1 640 (54.67%), and 616 (20.53%) patients, respectively. The rates of management according to the process in patients with high, medium and low comprehensive risk of cardiovascular disease were 94.49% (703 cases), 88.10% (1 445 cases) and 100% (616 cases), respectively. Conclusion The elderly patients with chronic disease in primary care with combined application of mobile smart healthcare technology and arrhythmia, HRV, OSAHS analysis methods to the prevention and control of cardiovascular diseases have higher detection rate of cardiovascular disease risk and management rate, which is conducive to the establishment of a cardiovascular disease prevention and control system for them.

A common complication of stroke patients is post-stroke cognitive impairment (PSCI) , which significantly reduces their quality of life. There are no effective targeted treatment measures currently available for PSCI in clinical practice. A large number of studies have already indicated that the activation of NLRP3 inflammasome plays a crucial role in PSCI, and many inhibitory treatments have been shown to improve cognitive impairment. The purpose of this study was to summarized the activation and modulating factors of NLRP3 inflammatory bodies and the relationship with PSCI. Some studies have been demonstrated that inhibiting NLRP3 or its associated inflammatory body components reduces the inflammatory response, promoting cognitive function recovery in cell and animal models of PSCI. Consequently, targeting NLRP3 inflammatory bodies may be a new trends of dealing with PSCI treatment. Despite the fact that numerous drugs and therapeutic measures have been proved to suppress the activation of NLRP3 inflammatory bodies, their clinical efficacy and safety have not yet been confirmed.

Despite the availability of various drugs for the treatment of diabetes worldwide, many patients still fail to achieve the recommended target blood sugar levels. Therefore, it is urgent to develop and apply new hypoglycemic drugs. In May 2022, FDA approved tirzepatide, a dual receptor agonist for GIP and GLP-1, administrated once a week to improve blood glucose control in adults with type 2 diabetes by assisting diet and exercise. Numerous clinical studies have proven its effectiveness and safety in type 2 diabetes, and its potential applications in obesity, cardiovascular diseases, non-alcoholic steatohepatitis and so on. In this paper, the mechanism of action, efficacy and safety of tirzepatide were reviewed to provide a reference for its clinical application after marketed in China.

Background Chronic obstructive pulmonary disease (COPD) is a common respiratory disease that is associated with high risk of disability and mortality. Although evidence suggests that fatigue may induce acute exacerbation in COPD, it needs to be further tested. Objective To explore the relationship between fatigue and the acute exacerbation in COPD. Methods By use of convenient sampling, a total of 597 COPD patients were selected from the First Affiliated Hospital of Bengbu Medical College, the Second Affiliated Hospital of Bengbu Medical College and the Third People's Hospital of Bengbu to establish a cohort study population between March 2019 and October 2020. During the hospitalization, general information such as gender, age, educational level, marital status, living style, comorbidities, smoking history, and monthly family income were collected from patients. Fatigue Scale-14 was used to measure the fatigue status, BODE index was used to predict the severity and prognosis, Anxiety and depression were assessed by the Anxiety Scale (HADS-A) and the Depression Scale (HADS-D) in the Hospital Anxiety and Depression Scale (HADS) . The patients were followed up for 1 year after discharge, recorded the occurrence of acute exacerbation in COPD, and assessed the quality of life with COPD Assessment Test (CAT) . Univariate analysis and multivariate Cox regression analysis were performed to identity factors possibly associated with the acute exacerbation in COPD. ROC curve analysis was used to measure the performance of fatigue in predicting acute exacerbation in COPD. Results The lost cases were screened and eliminated according to the corresponding inclusion criteria and exclusion criteria, five hundred and fifty cases were finally included for analysis, 416 of them had fatigue, and other 134 did not. Patients with and without fatigue had significant differences in smoking prevalence, mean number of acute exacerbations in a year, BODE index, HADS-A score, and CAT score (P

Background and purpose: The treatment-related cardiovascular disease in patients with breast cancer poses a greater mortality threat than cancer itself. To assist clinical oncologist, we introduced a scale to help clinicians by screening out patients with breast cancer who were at risk of cardiovascular diseases. The breast cancer patients in Zhongshan Hospital, Fudan University were analyzed retrospectively by the scale. Methods: This was a single center, retrospective trial. A total of 760 patients who met the inclusion and exclusion criteria were enrolled in this trial from January 1, 2017 to December 31, 2018. The incidence rate of cardiovascular risk was collected from patients eligible for admission. Secondly, follow-up information for each patient was evaluated by the scale and the clinician. The repeatability, sensitivity, specificity and consistency of the scale were evaluated. Results: The average follow-up duration was (746.55±309.94) d, and the average population age was (56.60±12.62) years. A total of 36 patients developed severe arrhythmias during or after the treatment, 8 patients with emerging myocardial injury and 6 patients with emerging cardiac insufficiency. The follow-up rates of patients with test for NT-proBNP from half a year to one year and more than one year after baseline were 34.31% and 29.62%, while 35.48% and 32.48% for those who took echocardiography. The sensitivity, specificity and overall accuracy of medium-and high-risk patient tests were 0.828, 0.934 and 0.921, respectively. The sensitivity, specificity and overall accuracy of high-risk patient tests were 0.983, 0.986, and 0.986, respectively. The linear consistency with clinical judgment was κ=0.633, P